ATP128 + VSV-GP128 + ezabenlimab

ATP128 + VSV-GP128 + ezabenlimab is an experimental combination immunotherapy comprised of three components: - **ATP128**: a self-adjuvanted chimeric recombinant protein cancer vaccine developed using the KISIMA platform. ATP128 contains three colorectal cancer-associated antigens (CEA, survivin, ASCL2), a proprietary cell-penetrating peptide for intracellular antigen delivery, and a Toll-like receptor (TLR)-peptide agonist for self-adjuvancy. It activates antigen-presenting cells and induces a strong T cell-mediated immune response through TLR2 and TLR4 signaling, triggering both NF-kB and IRF3 pathways[3][5]. - **VSV-GP128**: a recombinant vesicular stomatitis virus (Indiana strain) genetically engineered to express the glycprotein GP from a non-neurotropic strain of lymphocytic choriomeningitis virus (LCMV) and incorporating the same antigenic domain as ATP128. VSV-GP128 acts as an oncolytic viral vaccine, designed for use as a boost after ATP128 (heterologous prime-boost strategy) and induces potent, persistent antigen-specific cytotoxic T cells[1][5]. - **ezabenlimab (BI 754091)**: a fully human IgG4 monoclonal antibody that inhibits programmed cell death 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor T cell activity[1][5]. The combination aims to elicit robust, durable anti-cancer immunity in patients with microsatellite stable or mismatch repair proficient (MSS/MMRp) colorectal cancer, particularly those not responsive to PD-1 blockade alone. It is under investigation in phase 1b trials primarily for stage IV colorectal cancer[1][2][3][4][5].

Other names

ATP128 + VSV-GP128 + BI 754091KISIMA-01 (for the trial)BI 754091 (alternative for ezabenlimab)